Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 14

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 14
---
 to this prospectus, and their respective donees, pledgees, assignees, transferees or other successors-in-interestselling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer. In accordance with the terms of the Registration Rights Agreement, this prospectus covers the resale of the maximum number of shares of common stock issuable upon exercise of the Warrants without regard to any limitations on the exercise of such warrants. Under the terms of the Pre-FundedWarrants and Common Warrants held by selling stockholders, a selling stockholder may elect to the extent such exercise would cause such selling stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding shares common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such Warrants that have not been exercised, to instead receive a Pre-FundedWarrant in lieu of shares of common stock. The shares of common stock reported under “Number of Shares Owned” and “Number of Shares Being Offered” in the table below do not give effect to any such beneficial ownership limitation. The table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling stockholders as of April 2, 2025, assuming the full exercise of the Warrants held by the selling stockholders on that date, without regard to any limitations on exercises. As of March 21, 2025, we had 16,999,626 shares of common stock issued and outstanding. The following table also provides the number of shares of common stock that may be sold by each selling stockholder under this prospectus and that each selling stockholder will beneficially own assuming all the shares of common stock that may be offered pursuant to this prospectus are sold. Because each selling stockholder may dispose of all, none or some portion of their shares of common stock, no estimate can be given as to the number of shares of common stock that will be beneficially owned by a selling stockholder upon termination of this offering. For purposes of the table below, however, we have assumed that after termination of this offering none of the shares of common stock covered by this prospectus will be beneficially owned by the selling stockholders and further assumed that the